Compare Manchester United PLC (MANU) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manchester United PLC vs ResMed Inc. — how do they compare? Manchester United PLC trades at $22.85 (market cap $3.80B), while ResMed Inc. trades at $224.32 (market cap $32.61B). The key difference: ResMed Inc. is far larger — about 8.6× Manchester United PLC's market cap, and Manchester United PLC pays the higher dividend (1.26%). Which is the better fit depends on your goals.
| MANU | RMD | |
|---|---|---|
Market Cap | $3.80B | $32.61B |
Sector | Media | Health |
52-Week High | $23.53 | $293.73 |
52-Week Low | $15.10 | $182.82 |
Enterprise Value | $4.74B | $31.97B |
Dividend Yield | 1.26% | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Manchester United (MANU) trades at $21.70, up 0.32% on the day, with a bearish technical signal but improving fundamentals. Recent Q1 2026 earnings beat expectations, though the company remains unprofitable with a net income margin of -2.65%. Key developments include securing land for a new 100,000-seat stadium and Champions League qualification, which may boost future revenue.
The outlook is mixed: operational improvements and stadium plans offer long-term growth potential, but persistent losses, high debt, and weak cash conversion pose risks. Analyst sentiment is cautious with 40% buy ratings. Investors should weigh recovery prospects against financial stability concerns.
ResMed (RMD) trades at $221.22, up 0.53% with a bullish technical signal and strong fundamental performance. The company delivered four consecutive quarterly earnings beats, with Q4 2026 EPS of $2.95 beating expectations by 2.1%. Revenue grew 9% year-over-year to $1.5 billion, while maintaining robust profitability with 61.1% gross margins and 26.9% net income margins. Recent strategic moves include the $490 million sale of MatrixCare to focus on core sleep and respiratory care markets.
The stock presents a compelling growth story with consistent execution, though near-term headwinds from weak 2027 revenue guidance create uncertainty. Analyst consensus targets $235.00 (6.2% upside) with 40% buy ratings. Key risks include ventilator sales suspension, cost pressures, and competitive threats in the medical device space. The company's strong cash flow generation and shareholder returns ($1.0 billion in 2026) support long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Manchester United PLC
Manchester United PLC operates a professional football club together with related and ancillary activities. The company manages the soccer team and all affiliated club activities of the Manchester United Football Club, which includes the media network, foundation, fan zone, news, sports features, and team merchandise. Manchester United is based in England. The company has three principal sectors from which most of the revenue is generated, including Commercial, Broadcasting, and Matchday.
Read more on MANU →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
